Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Metalyse er større end risiciene for patienter, der har behov for trombolytisk behandling som følge af formodet myokardieinfarkt.
The Committee for Medicinal Products for Human Use (CHMP) decided that Metalyse’ s benefits are greater than its risks for patients requiring thrombolytic treatment because of suspected myocardial infarction.